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nonindustry-funded studies (45% and 41%, re-
spectively; P = 0.88 by chi-square test).
In randomized, controlled trials in critical 
care medicine that were published in the ICMJE 
journals with the highest impact factor, a sub-
stantial proportion of trials do not produce sec-
ondary publications. Because established trial 
groups are more likely to publish secondary 
analyses than independent groups, this difference 
may represent a missed opportunity in advanc-
ing scientific discovery and hypothesis genera-
tion that could be addressed through responsible 
data sharing. There appears to be a considerable 
delay between the publication of original and 
secondary analyses. We submit that these ob-
servations be taken into consideration in devel-
oping guidelines for data sharing to maximize 
opportunities and benefits for primary and sec-
ondary investigators. (Our database will be made 
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Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant 
Recipients
To the Editor: Hepatitis C virus (HCV) infec-
tion continues to be the most frequent indication 
for liver transplantation, but recurrence of infec-
tion is nearly universal in patients who are vire-
mic at the time of transplantation.1 Direct-acting 
antiviral agents (DAAs) have been shown to be 
effective in treating recurrent HCV infection2,3 
but have not been tested in preventing reinfec-
tion at the time of liver transplantation. Be-
cause HCV RNA levels fall precipitously after 
liver transplantation owing to removal of the 
liver, the immediate perioperative period before 
rebound of viremia represents a unique oppor-
tunity to cure HCV infection.4 We hypothesized 
that a DAA regimen shorter than the standard 
12 to 24 weeks starting immediately before the 
transplantation might prevent reinfection of the 
new graft.
We conducted an open-label, multicenter, phase 
2 study (ClinicalTrials.gov number, NCT02350569) 
involving wait-listed patients with chronic HCV 
genotype 1 infection who were undergoing a first 
liver transplantation from an HCV-negative donor. 
Patients who had received previous DAA treat-
ment or who had a creatinine clearance of less 
than 40 ml per minute at the time of transplan-
tation were excluded. A total of 37 patients were 
screened, and 16 with a median unadjusted 
Model for End-Stage Liver Disease score of 13 
(on a scale from 6 to 40, with higher scores in-
dicating more advanced liver disease) were en-
rolled (Fig. S1 and Table S1 in the Supplemen-
tary Appendix, available with the full text of this 
letter at NEJM.org). Patients received a single dose 
of ledipasvir (90 mg)–sofosbuvir (400 mg) the 
day they arrived at the hospital for transplanta-
tion and once daily for 4 weeks postoperatively. 
The primary efficacy end point was a sustained 
virologic response 12 weeks after the end of the 
4-week treatment. Deep sequencing of HCV NS5A 
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and NS5B was performed for all recipients at 
baseline.
Figure 1 shows HCV RNA levels from day −1 
to the end of study. The rate of sustained viro-
logic response for the 4-week course was 88% 
(Table S2 in the Supplementary Appendix). One 
patient had a relapse after the 4 weeks, but a 
sustained virologic response was achieved after 
retreatment with 12 weeks of ledipasvir–sofos-
buvir per the study protocol, leading to an over-
all cure in 15 of the 16 patients (94%). This 
patient had three NS5A resistance-associated 
substitutions at study enrollment. One patient 
discontinued treatment after the creatinine 
clearance fell below a predefined threshold of 
30 ml per minute on day 5. Overall, 88% of the 
patients had adverse events after liver transplan-
tation, and 31% had serious adverse events (Ta-
bles S3 and S4 in the Supplementary Appendix). 
No patient discontinued treatment owing to an 
adverse event, had graft loss, or died.
In this trial of preemptive therapy in HCV-
positive patients undergoing liver transplantation, 
a 4-week course of perioperative ledipasvir– 
sofosbuvir led to a high rate of sustained viro-
logic response, suggesting that it may be an ef-
fective approach for preventing HCV recurrence. 
The only patient with a virologic relapse had 
NS5A resistance at baseline and had a response 
to an additional 12 weeks of therapy, suggesting 
that baseline resistance testing may guide the 
need for standard courses of therapy. This new 
perioperative approach needs to be tested in dif-
ferent populations, such as repeat or combined 
organ recipients and patients with previous DAA 
treatment failures, and in those with advanced 
renal failure (other DAAs). In addition, there may 
be an opportunity to test modifications of this 
approach in liver or other solid organ recipients 
being offered HCV-positive organs as a way to 
increase the donor pool and number of trans-
plants.
Figure 1. Hepatitis C Virus (HCV) RNA Levels from Day –1 to Post-Treatment Week 12.
The black curves represent the patients who had a sustained virologic response 12 weeks after the end of the 
4-week treatment. The green curve represents a patient who had a relapse after initial treatment and had a sus-
tained virologic response after 12 weeks of retreatment. The orange curve represents a patient who discontinued 
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15TH ANNUAL MILD COGNITIVE IMPAIRMENT 
SYMPOSIUM
The symposium, along with a workshop and public forum, 
will be held in Miami Beach, FL, Jan. 14 and 15. It is presented 
by the Wien Center for Alzheimer’s Disease and Memory Dis-
orders, Mount Sinai Medical Center.
Contact MCI Symposium 2017, c/o World Events Forum, 
1631 Whitcomb Ave., Des Plaines, IL 60018; or call (224) 938-
9523; or e-mail meetings@worldeventsforum.com; or see http://
www.mcisymposium.org.
10TH INTERNATIONAL CONFERENCE ON ACUTE 
CARDIAC CARE
The conference will be held in Tel Aviv, Israel, Jan. 15–17.
Contact the Secretariat, 10th International Conference – 
ACC2017, P.O. Box 574, Jerusalem 91004, Israel; or call 972-2-
6520574; or fax 972-2-6520558; or e-mail seminars@isas.co.il; 
or see http://www.acute-cardiac-care.com.
11TH ANNUAL DRUG DISCOVERY FOR 
NEURODEGENERATION CONFERENCE
The conference will be held in San Diego, CA, Feb. 12–14. It 
is presented by the Alzheimer’s Drug Discovery Foundation.
Contact Sara Classen, Scientific Events, Alzheimer’s Drug 
Discovery Foundation, 57 W. 57th St., Suite 904, New York, NY 
10019; or call (212) 901-8009; or fax (212) 901-8010; or e-mail 
sclassen@alzdiscovery.org; or see http://worldeventsforum.com/
addf/drugdiscovery.
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